DE2803397C2 - - Google Patents

Info

Publication number
DE2803397C2
DE2803397C2 DE2803397A DE2803397A DE2803397C2 DE 2803397 C2 DE2803397 C2 DE 2803397C2 DE 2803397 A DE2803397 A DE 2803397A DE 2803397 A DE2803397 A DE 2803397A DE 2803397 C2 DE2803397 C2 DE 2803397C2
Authority
DE
Germany
Prior art keywords
active substance
iap
substance
protein
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2803397A
Other languages
German (de)
English (en)
Other versions
DE2803397A1 (de
Inventor
Motoyuki Ohtsu Shiga Jp Yajima
Koichi Shiga Jp Hosoda
Chikanori Ohtsu Shiga Jp Tomioka
Michio Sapporo Hokkaido Jp Ui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of DE2803397A1 publication Critical patent/DE2803397A1/de
Application granted granted Critical
Publication of DE2803397C2 publication Critical patent/DE2803397C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE19782803397 1977-02-01 1978-01-26 Biologisch aktive substanz, verfahren zu deren herstellung und dieselbe enthaltendes mittel Granted DE2803397A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1039777A JPS5396392A (en) 1977-02-01 1977-02-01 Active substance for increasing secretion of insulin

Publications (2)

Publication Number Publication Date
DE2803397A1 DE2803397A1 (de) 1978-08-03
DE2803397C2 true DE2803397C2 (OSRAM) 1990-01-25

Family

ID=11748989

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19782803397 Granted DE2803397A1 (de) 1977-02-01 1978-01-26 Biologisch aktive substanz, verfahren zu deren herstellung und dieselbe enthaltendes mittel

Country Status (19)

Country Link
US (1) US5000953A (OSRAM)
JP (1) JPS5396392A (OSRAM)
AU (1) AU513963B2 (OSRAM)
BE (1) BE863477A (OSRAM)
CA (1) CA1105863A (OSRAM)
CH (1) CH640244A5 (OSRAM)
CS (1) CS216547B2 (OSRAM)
DE (1) DE2803397A1 (OSRAM)
DK (1) DK152058B (OSRAM)
ES (1) ES467067A1 (OSRAM)
FR (1) FR2378793A1 (OSRAM)
GB (1) GB1569046A (OSRAM)
HU (1) HU179497B (OSRAM)
IE (1) IE46649B1 (OSRAM)
NL (1) NL7801137A (OSRAM)
NZ (1) NZ186361A (OSRAM)
SE (1) SE7801106L (OSRAM)
SU (1) SU871721A3 (OSRAM)
ZA (1) ZA7855B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59206316A (ja) * 1983-05-11 1984-11-22 Kaken Pharmaceut Co Ltd インシユリン分泌増強活性物質誘導体およびその製法
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
AU2001254621A1 (en) * 2000-05-05 2001-11-20 K.U. Leuven R And D Critical illness neuropathy
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia
US20030199445A1 (en) * 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients

Also Published As

Publication number Publication date
SE7801106L (sv) 1978-08-02
ES467067A1 (es) 1978-11-01
DE2803397A1 (de) 1978-08-03
AU3285478A (en) 1979-08-09
NL7801137A (nl) 1978-08-03
FR2378793B1 (OSRAM) 1982-10-22
SU871721A3 (ru) 1981-10-07
GB1569046A (en) 1980-06-11
CS216547B2 (en) 1982-11-26
HU179497B (en) 1982-10-28
DK152058B (da) 1988-01-25
ZA7855B (en) 1978-11-29
IE46649B1 (en) 1983-08-10
JPS5396392A (en) 1978-08-23
IE780205L (en) 1978-08-01
DK45378A (da) 1978-08-02
JPS5635154B2 (OSRAM) 1981-08-14
CA1105863A (en) 1981-07-28
BE863477A (fr) 1978-07-31
FR2378793A1 (fr) 1978-08-25
CH640244A5 (en) 1983-12-30
US5000953A (en) 1991-03-19
NZ186361A (en) 1980-10-08
AU513963B2 (en) 1981-01-15

Similar Documents

Publication Publication Date Title
EP0049847B1 (de) Alpha-Amylaseinaktivator, Verfahren zu seiner Herstellung, Mittel auf Basis dieses Inaktivators sowie dieser Inaktivator zur Regulierung des Blutzuckerspiegels
DE2331144A1 (de) Wasserloesliche extrakte von mycobacterien
EP0151246A2 (de) Neue Polypeptide mit alpha-Amylase-hemmender Wirkung, Verfahren zu deren Herstellung, deren Verwendung und pharmazeutische Präparate
DE68906735T2 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
DE2628914C2 (OSRAM)
DE3429551C2 (OSRAM)
DE3687097T2 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE2825464A1 (de) Biologisch aktive substanz, verfahren zu deren herstellung und dieselbe enthaltendes pharmazeutisches mittel
DE69315388T2 (de) Aus bakteriellen Proteinen bestehender Extrakt, Verfahren zur dessen Herstellung und diesen Extrakt enthaltende pharmazeutische Zusammensetzung
DE2803397C2 (OSRAM)
EP0101063A2 (de) Neues Polypeptid mit Wirkung auf das Immunsystem, Verfahren zu seiner Isolierung und Reinigung, seine Verwendung und dieses enthaltende Mittel
DE3109335A1 (de) Die neue, physiologisch wirksame substanz ebelacton und verfahren zur herstellung derselben
DD215580A5 (de) Hypocholesterolaemisch aktives protein
DE2734150B2 (de) Verfahren zur Herstellung von Human-Lysozympräparaten
DE68903065T2 (de) Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien.
DE2558537C2 (de) Verfahren zum Isolieren von Substanzen mit insulinähnlicher Wirksamkeit aus Blut oder Blutbestandteilen von Kälbern oder Schweinen
DE2701890A1 (de) Alpha-amylase-inhibitor aus einem streptomyceten und verfahren zu seiner gewinnung
DE1076888B (de) Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke
DE2234832C2 (de) Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate
CH657989A5 (de) Biologisch aktive substanz, verfahren zur herstellung der substanz, sowie die substanz enthaltende, immunoaktive zusammensetzung.
DE3644805C2 (OSRAM)
CH640865A5 (de) Glykoproteid des menschlichen urins, verfahren zu seiner herstellung und mittel zur bekaempfung von leukozytopenie.
DE2639410C2 (de) Polypeptid VI-7501 mit Antitumorwirkung
CH639667A5 (de) Verfahren zur herstellung von peptidkomplexen aus dns-haltigen organismen.
DE2146674C3 (de) Faktor und seine Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: KAKEN PHARMACEUTICAL K.K., TOKIO/TOKYO, JP

8128 New person/name/address of the agent

Representative=s name: DEUFEL, P., DIPL.-WIRTSCH.-ING.DR.RER.NAT. SCHOEN,

D2 Grant after examination
8364 No opposition during term of opposition
8330 Complete disclaimer